These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7356882)

  • 1. The kinetics of propranolol in hypothyroidism [proceedings].
    Riddell JG; Neill JD; Kelly JG; McDevitt DG
    Br J Clin Pharmacol; 1980 Jan; 9(1):121P. PubMed ID: 7356882
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of thyroid dysfunction on propranolol kinetics.
    Riddell JG; Neill JD; Kelly JG; McDevitt DG
    Clin Pharmacol Ther; 1980 Nov; 28(5):565-74. PubMed ID: 7438675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies of the effect of thyroid dysfunction on the elimination of beta-adrenoreceptor blocking drugs.
    Bell JM; Russell CJ; Nelson JK; Kelly JG; McDevitt DG
    Br J Clin Pharmacol; 1977 Feb; 4(1):79-82. PubMed ID: 14661
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of propranolol on extrathyroidal metabolism of thyroxine and 3,3',5-triiodothyronine evaluated by noncompartmental kinetics.
    Lumholtz IB; Siersbaek-Nielsen K; Faber J; Kirkegaard C; Friis T
    J Clin Endocrinol Metab; 1978 Sep; 47(3):587-9. PubMed ID: 263312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propranolol kinetics in hyperthyroidism [proceedings].
    Riddell JG; Neill JD; Kelly JG; McDevitt DG
    Br J Clin Pharmacol; 1979 Oct; 8(4):386P-387P. PubMed ID: 508523
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical pharmacokinetics of beta-adrenoceptor blocking drugs in thyroid disease.
    Feely J
    Clin Pharmacokinet; 1983; 8(1):1-16. PubMed ID: 6132696
    [No Abstract]   [Full Text] [Related]  

  • 7. Altered pharmacokinetics of propranolol in hyperthyroidism [proceedings].
    Feely J; Crooks J; Stevenson IH
    Br J Clin Pharmacol; 1979 Oct; 8(4):387P. PubMed ID: 508524
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pharmacokinetics of propranolol in patients with chronic renal insufficiency undergoing hemodialysis].
    Flouvat B; Decourt S; Potaux L
    Therapie; 1979; 34(1):63-72. PubMed ID: 483227
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of the beta-adrenoceptor blocking properties and pharmacokinetics of SL 75212 and propranolol in man [proceedings].
    Bianchetti G; Chauvin M; Giudicelli JF; Gomeni R; Kilborn JR; Morselli PL; Richer C; Thuillez C
    Br J Clin Pharmacol; 1979 Oct; 8(4):407P-708P. PubMed ID: 41559
    [No Abstract]   [Full Text] [Related]  

  • 10. Roles of hepatic blood flow and enzyme activity in the kinetics of propranolol and sotalol.
    Pirttiaho HI; Sotaniemi EA; Pelkonen RO; Pitkänen U; Anttila M; Sundqvist H
    Br J Clin Pharmacol; 1980 Apr; 9(4):399-405. PubMed ID: 7378257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of metoclopramide on the bioavailability of long-acting propranolol.
    Charles BG; Renshaw PJ; Kay JJ; Ravenscroft PJ
    Br J Clin Pharmacol; 1981 May; 11(5):517-8. PubMed ID: 7272164
    [No Abstract]   [Full Text] [Related]  

  • 12. Biological determinants of propranolol disposition in man.
    Kornhauser DM; Wood AJ; Vestal RE; Wilkinson GR; Branch RA; Shand DG
    Clin Pharmacol Ther; 1978 Feb; 23(2):165-74. PubMed ID: 620476
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of age and cigarette smoking on propranolol disposition.
    Vestal RE; Wood AJ; Branch RA; Shand DG; Wilkinson GR
    Clin Pharmacol Ther; 1979 Jul; 26(1):8-15. PubMed ID: 445965
    [No Abstract]   [Full Text] [Related]  

  • 14. Cyclic adenosine 3',5'-monophosphate concentration in plasma, adipose tissue and skeletal muscle in normal subjects and in patients with hyper- and hypothyroidism.
    Karlberg BE; Henriksson KG; Andersson RG
    J Clin Endocrinol Metab; 1974 Jul; 39(1):96-101. PubMed ID: 4365918
    [No Abstract]   [Full Text] [Related]  

  • 15. Naphthoxylactic acid after single and long-term doses of propranolol.
    Walle T; Conradi EC; Walle UK; Fagan TC; Gaffney TE
    Clin Pharmacol Ther; 1979 Nov; 26(5):548-54. PubMed ID: 498695
    [No Abstract]   [Full Text] [Related]  

  • 16. Plasma protein binding of propranolol and isoprenaline in hyperthyroidism and hypothyroidism.
    Kelly JG; McDevitt DG
    Br J Clin Pharmacol; 1978 Aug; 6(2):123-7. PubMed ID: 678388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemodynamic and pharmacokinetic study of propranolol and atenolol in cirrhosis patients.
    Rocher I; Decourt S; Leneveu A; Lebrec D; Rosier SP; Flouvat B
    Int J Clin Pharmacol Ther Toxicol; 1985 Aug; 23(8):406-10. PubMed ID: 4044073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of a fixed combination with propranolol, hydrochlorothiazide and triamterene.
    Felder K; Geissler HE; Hiemstra S; Mutschler E; Schäfer M; Ziegler E
    Arzneimittelforschung; 1979; 29(11):1746-52. PubMed ID: 543886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis and disposition of low dose oral propranolol.
    MacKichan JJ; Pyszczynski DR; Jusko WJ
    Res Commun Chem Pathol Pharmacol; 1978 Jun; 20(3):531-8. PubMed ID: 674830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of SL 75212 and propranolol in old age, uraemia and in healthy young adults [proceedings].
    Bianchetti G; Brancaccio D; Forette F; Henry JF; Hervy MP; Ganansia J; Gomeni R; Kilborn JR; Morselli PL
    Br J Clin Pharmacol; 1980 Mar; 9(3):299P. PubMed ID: 6102472
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.